Filing Flows

Filing Flows › Black Diamond Therapeutics (BDTX) › Recalls, complaints & regulation

Black Diamond Therapeutics (BDTX): recalls, EPA violations and clinical trials

Black Diamond Therapeutics (BDTX) beyond its filings: 0 recalls in the last 12 months (6 in five years, 0 Class I); 5 EPA-regulated facilities in violation, no penalties in five years; 2 active clinical trials.

Latest recalls

EPA facilities in violation

Facility (as registered)CityStatusPenalties
BLACK DIAMOND RETAIL SOUTHBlack Diamond, WASignificant Violation—
BLACK DIAMOND AUTO WRECKING 1100Black Diamond, WAViolation Identified—
BLACK DIAMOND CITY OFBlack Diamond, WAViolation Identified—
BLACK DIAMOND GOLF COURSE PWS, OHViolation Identified—
BLACK DIAMOND TOWN CENTER PHASES 1 AND 2Lecanto, FLViolation Identified—

Facilities in the EPA's ECHO register whose registered name matches the company's; a facility can belong to another business of the same name.

Black Diamond Therapeutics' latest quarter

Black Diamond Therapeutics, Q1 2025: revenue $70.0M, operating margin 77.9%, net earnings $56.5M, operating cash flow $53.4M. The chart follows the revenue to costs, profit and cash.

Questions

Has Black Diamond Therapeutics had any recalls?

6 recalls on file over five years from the FDA, CPSC and NHTSA; 0 in the last 12 months.

Has Black Diamond Therapeutics been fined by the EPA?

The 96 EPA-regulated facilities on file under its name drew no penalties in five years; 5 are in violation now.

How many clinical trials does Black Diamond Therapeutics have?

2 active studies on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.